Dabigatran ethyl ester hydrochloride is primarily used as a prodrug of dabigatran, a direct thrombin inhibitor. Its main application is in the prevention and treatment of thromboembolic disorders, such as stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also prescribed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the prevention of these conditions following orthopedic surgeries like hip or knee replacement. The compound offers an alternative to traditional anticoagulants like warfarin, providing a more predictable anticoagulant effect without the need for frequent blood monitoring. Its oral bioavailability and rapid conversion to the active form make it a convenient option for long-term management of clotting disorders.